Complementary medicines in psychiatry
| Autor: | Ursula Werneke, Trevor Turner, Stefan Priebe |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Complementary Therapies
Valerian S-Adenosylmethionine medicine.medical_specialty Substance-Related Disorders Alternative medicine Placebo-controlled study Tardive dyskinesia Selenium Ergoloid Mesylates Folic Acid medicine Humans Hypnotics and Sedatives Adverse effect Psychiatry Nootropic Agents Dyskinesias biology business.industry Mental Disorders medicine.disease biology.organism_classification Mental health Antidepressive Agents Clinical trial Psychiatry and Mental health Schizophrenia Dementia Plant Preparations Cognition Disorders business Antipsychotic Agents Phytotherapy |
| Zdroj: | British Journal of Psychiatry. 188:109-121 |
| ISSN: | 1472-1465 0007-1250 |
| Popis: | BackgroundThe use of complementary medicines in those with mental health problems is well documented. However, their effectiveness is often not established and they may be less harmless than commonly assumed.AimsTo review the complementary medicines routinely encountered in psychiatric practice, their effectiveness, potential adverse effects and interactions.MethodElectronic and manual literature search on the effectiveness and safety of psychotropic complementary medicines.ResultsPotentially useful substances include ginkgo and hydergine as cognitive enhancers, passion flower and valerian as sedatives, St John's wort and sadenosylmethionine as antidepressants, and selenium and folate to complement antidepressants. The evidence is less conclusive for the use of omega-3 fatty acids as augmentation treatment in schizophrenia, melatonin for tardive dyskinesia and 18-methoxycoronaridine, an ibogaine derivative, for the treatment of cocaine and heroin addiction.ConclusionsSystematic clinical trials are needed to test promising substances. Meanwhile, those wishing to take psychotropic complementary medicines require appropriate advice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|